Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Development of AO-176, a Next Generation Humanized Anti-CD47 Antibody With Novel Anti-Cancer Properties and Negligible Red Blood Cell Binding.

Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, Frazier WA, Karr RW, Pereira DS.

Mol Cancer Ther. 2019 Dec 26. pii: molcanther.1079.2019. doi: 10.1158/1535-7163.MCT-19-1079. [Epub ahead of print]

2.

A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.

Rajnavölgyi E, Nagy N, Thuresson B, Dosztányi Z, Simon A, Simon I, Karr RW, Ernberg I, Klein E, Falk KI.

Int Immunol. 2000 Mar;12(3):281-93.

PMID:
10700463
4.
5.

HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides.

Trotter JL, Damico CA, Cross AH, Pelfrey CM, Karr RW, Fu XT, McFarland HF.

J Neuroimmunol. 1997 May;75(1-2):95-103.

PMID:
9143242
6.
7.

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD.

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3357-61.

8.

Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone.

Shornick LP, De Togni P, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Ferguson TA, Chaplin DD.

J Exp Med. 1996 Apr 1;183(4):1427-36.

9.
10.

Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).

Morton PA, Fu XT, Stewart JA, Giacoletto KS, White SL, Leysath CE, Evans RJ, Shieh JJ, Karr RW.

J Immunol. 1996 Feb 1;156(3):1047-54.

PMID:
8557978
11.
12.

Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401.

Woulfe SL, Bono CP, Zacheis ML, Kirschmann DA, Baudino TA, Swearingen C, Karr RW, Schwartz BD.

Arthritis Rheum. 1995 Dec;38(12):1744-53.

PMID:
8849346
13.

Structural requirements of peptide and MHC for DR(alpha, beta 1*0401)-restricted T cell antigen recognition.

McNicholl JM, Whitworth WC, Oftung F, Fu X, Shinnick T, Jensen PE, Simon M, Wohlhueter RM, Karr RW.

J Immunol. 1995 Aug 15;155(4):1951-63.

PMID:
7636246
14.

Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.

Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK.

J Immunol. 1995 Aug 1;155(3):1032-6.

PMID:
7543510
15.

Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.

Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ.

J Clin Invest. 1995 Aug;96(2):987-93.

16.

HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes.

Fu XT, Drover S, Marshall WH, Karr RW.

Hum Immunol. 1995 Aug;43(4):243-50.

PMID:
7499171
17.

Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.

Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW.

J Clin Invest. 1995 Jun;95(6):2783-9.

18.

Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association.

Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F.

J Exp Med. 1995 May 1;181(5):1847-55.

19.

Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide.

Fu XT, Bono CP, Woulfe SL, Swearingen C, Summers NL, Sinigaglia F, Sette A, Schwartz BD, Karr RW.

J Exp Med. 1995 Mar 1;181(3):915-26.

20.
21.

T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain.

Geluk A, Fu XT, van Meijgaarden KE, Jansen YY, De Vries RR, Karr RW, Ottenhoff TH.

Eur J Immunol. 1994 Dec;24(12):3241-4.

PMID:
7805754
22.

Acidic residues in the DR beta chain third hypervariable region are required for stimulation of a DR(alpha, beta 1*0402)-restricted T-cell clone.

Olson RR, Reuter JJ, McNicholl J, Alber C, Klohe E, Callahan K, Siliciano RF, Karr RW.

Hum Immunol. 1994 Nov;41(3):193-200.

PMID:
7868374
23.

Different regions of the N-terminal domains of HLA-DR1 influence recognition of individual peptide-DR1 complexes.

Tuosto L, Karr RW, Fu XT, Olson RR, Cundari E, Piccolella E, Lechler R, Lombardi G.

Hum Immunol. 1994 Aug;40(4):312-22.

PMID:
7528190
24.

Amino acids in the peptide-binding groove influence an antibody-defined, disease-associated HLA-DR epitope.

Drover S, Marshall WH, Kwok WW, Nepom GT, Karr RW.

Scand J Immunol. 1994 Jun;39(6):539-50.

PMID:
7516571
25.

Analysis of monoclonal antibodies specific for unique and shared determinants on HLA-DR4 molecules.

Drover S, Karr RW, Fu XT, Marshall WH.

Hum Immunol. 1994 May;40(1):51-60.

PMID:
7519185
27.

Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93.

Liu YN, Curtsinger J, Donahue PR, Klaus A, Optiz G, Cooper J, Karr RW, Bach FH, Gehrz RC.

J Gen Virol. 1993 Oct;74 ( Pt 10):2207-14.

PMID:
7691989
29.

Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen.

Panina-Bordignon P, Fu XT, Lanzavecchia A, Karr RW.

J Exp Med. 1992 Dec 1;176(6):1779-84.

30.

Critical role of HLA-DR beta 1 residue 58 in multiple polymorphic epitopes recognized by xenogeneic and allogeneic antibodies.

Klohe E, Pistillo MP, Ferrara GB, Goeken NE, Greazel NS, Karr RW.

Hum Immunol. 1992 Sep;35(1):18-28.

PMID:
1282512
31.
32.
33.

Identification of residues involved in polymorphic antibody binding epitopes on HLA-DR molecules.

Fu XT, Yu WY, Alber C, Benson C, Watts R, Nordwig H, Johnson JP, Knowles RW, Karr RW.

Hum Immunol. 1992 Jan;33(1):47-56.

PMID:
1372304
34.

Analysis of HLA specificity of human monoclonal antibodies by cytofluorimetry and cell ELISA.

Pistillo MP, Tazzari PL, Mazzoleni O, Urlacher A, Falco M, Vitale M, Karr RW, Ferrara GB.

Eur J Immunogenet. 1991 Oct-Dec;18(5-6):345-53.

PMID:
1772879
35.

DRw11 haplotypes: continuum of DRB1 diversity augmented by unique DQ/DRw52 associations.

Lee KW, Johnson AH, Tang T, Yu WY, Karr RW, Hurley CK.

Hum Immunol. 1991 Oct;32(2):150-5. Erratum in: Hum Immunol 1992 May;34(1):75.

PMID:
1744003
36.

MHC-antigen-T cell interactions: an overview.

Sette A, O'Sullivan D, Krieger JI, Karr RW, Lamont AG, Grey HM.

Semin Immunol. 1991 Jul;3(4):195-202. Review.

PMID:
1932703
37.

Polymorphic HLA-DR7 beta 1 chain residues that are involved in T cell allorecognition.

Rosen-Bronson S, Yu WY, Karr RW.

J Immunol. 1991 Jun 15;146(12):4264-70.

PMID:
2040801
38.

Antigen-specific T cells with monogamous or promiscuous restriction patterns are sensitive to different HLA-DR beta chain substitutions.

Karr RW, Panina-Bordignon P, Yu WY, Lanzavecchia A.

J Immunol. 1991 Jun 15;146(12):4242-7.

PMID:
2040799
39.

Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition.

Krieger JI, Karr RW, Grey HM, Yu WY, O'Sullivan D, Batovsky L, Zheng ZL, Colón SM, Gaeta FC, Sidney J, et al.

J Immunol. 1991 Apr 1;146(7):2331-40.

PMID:
1706393
40.

Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells.

Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, Siliciano RF.

J Immunol. 1991 Mar 1;146(5):1470-7.

PMID:
1704395
41.

Functional analysis of MHC class II-restricted T cells derived from a Caucasian with a DR4, Dw15, DQw8 haplotype.

Celis E, Karr RW, Gregersen PK, Reinsmoen NL.

Hum Immunol. 1990 Sep;29(1):31-41.

PMID:
2211188
42.

The role of polymorphic HLA-DR beta chain residues in presentation of viral antigens to T cells.

Karr RW, Yu W, Watts R, Evans KS, Celis E.

J Exp Med. 1990 Jul 1;172(1):273-83.

43.

Identification of cross-reactive T cell restriction epitopes located on the DR7 beta 1 and DR beta 4 molecules.

Bismuth G, Gouy H, Karr RW, Debré P.

Hum Immunol. 1990 Jul;28(3):271-83.

PMID:
1695622
45.

HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level.

Stunz LL, Karr RW, Anderson RA.

J Immunol. 1989 Nov 1;143(9):3081-6.

PMID:
2809218
46.

T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein.

Munk ME, Schoel B, Modrow S, Karr RW, Young RA, Kaufmann SH.

J Immunol. 1989 Nov 1;143(9):2844-9.

PMID:
2509558
47.

Multiple regions of HLA-DR beta 1 chains determine polymorphic epitopes recognized by monoclonal antibodies.

Alber CA, Watts R, Klohe EP, Drover S, Marshall WH, Radka SF, Karr RW.

J Immunol. 1989 Oct 1;143(7):2248-55.

PMID:
2476501
49.

Genetic restriction and fine specificity of human T cell clones reactive with rabies virus.

Celis E, Karr RW, Dietzschold B, Wunner WH, Koprowski H.

J Immunol. 1988 Oct 15;141(8):2721-8.

PMID:
2459225
50.

Analysis of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules.

Klohe EP, Watts R, Bahl M, Alber C, Yu WY, Anderson R, Silver J, Gregersen PK, Karr RW.

J Immunol. 1988 Sep 15;141(6):2158-64.

PMID:
2459201

Supplemental Content

Support Center